Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F, De Gooijer CJ, van Gulijk M, Lukkes M, Klaase L, Lievense LA, Waasdorp C, Jebbink M, Bootsma GP, Stigt JA, Biesma B, Kaijen-Lambers MEH, Mankor J, Vroman H, Cornelissen R, Baas P, Van der Noort V, Burgers JA, Aerts JG. Dammeijer F, et al. Among authors: jebbink m. EBioMedicine. 2021 Feb;64:103160. doi: 10.1016/j.ebiom.2020.103160. Epub 2021 Jan 27. EBioMedicine. 2021. PMID: 33516644 Free PMC article.
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
van Berge Henegouwen JM, Jebbink M, Hoes LR, van der Wijngaart H, Zeverijn LJ, van der Velden DL, Roepman P, de Leng WWJ, Jansen AML, van Werkhoven E, van der Noort V, van der Wekken AJ, de Langen AJ, Voest EE, Verheul HMW, Smit EF, Gelderblom H. van Berge Henegouwen JM, et al. Among authors: jebbink m. Eur J Cancer. 2022 Aug;171:114-123. doi: 10.1016/j.ejca.2022.05.009. Epub 2022 Jun 15. Eur J Cancer. 2022. PMID: 35716537 Free article.
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Jebbink M, de Langen AJ, Monkhorst K, Boelens MC, van den Broek D, van der Noort V, de Gooijer CJ, Mahn M, van der Wekken AJ, Hendriks L, Hashemi SMS, Paats MS, Dingemans AC, Smit EF. Jebbink M, et al. JTO Clin Res Rep. 2023 Feb 24;4(4):100481. doi: 10.1016/j.jtocrr.2023.100481. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37035409 Free PMC article.
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, Mathijssen RHJ. Veerman GDM, et al. Among authors: jebbink m. EClinicalMedicine. 2023 Apr 13;59:101955. doi: 10.1016/j.eclinm.2023.101955. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37125403 Free PMC article.
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC.
Gulikers JL, Veerman GDM, Jebbink M, Kruithof PD, Steendam CMJ, Boosman RJ, Mathijssen RHJ, Tjan-Heijnen VCG, Driessen JHM, Dursun S, Smit EF, Dingemans AC, van Geel RMJM, Croes S, Hendriks LEL. Gulikers JL, et al. Among authors: jebbink m. JTO Clin Res Rep. 2024 Feb 20;5(4):100656. doi: 10.1016/j.jtocrr.2024.100656. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38550297 Free PMC article.
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of EGFR mutated NSCLC patients developing leptomeningeal metastases: ORA-LM study.
van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, Compter A, Boltjes RPB, Sol N, Monkhorst K, van den Broek D, Smit EF, de Langen AJ, Brandsma D. van der Wel JWT, et al. Among authors: jebbink m. Neuro Oncol. 2024 Aug 7:noae138. doi: 10.1093/neuonc/noae138. Online ahead of print. Neuro Oncol. 2024. PMID: 39110039
The force of HER2 - A druggable target in NSCLC?
Jebbink M, de Langen AJ, Boelens MC, Monkhorst K, Smit EF. Jebbink M, et al. Cancer Treat Rev. 2020 Jun;86:101996. doi: 10.1016/j.ctrv.2020.101996. Epub 2020 Feb 28. Cancer Treat Rev. 2020. PMID: 32135383 Review.
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.
Jebbink M, van Werkhoven E, Mandjes IA, Wesseling J, Lips EH, Vrancken Peeters MJ, Loo CE, Sonke GS, Linn SC, Falo Zamora C, Rodenhuis S. Jebbink M, et al. Breast Cancer Res Treat. 2015 Aug;153(1):145-52. doi: 10.1007/s10549-015-3510-4. Epub 2015 Jul 26. Breast Cancer Res Treat. 2015. PMID: 26210520
97 results